Product Overview
The DRI Cocaine Metabolite Enzyme Immunoassay is a homogeneous enzyme immunoassay intended for the qualitative and semi-quantitative determination of benzoylecgonine (Cocaine Metabolite) in human urine
Product Features
-
Specifically designed to test for Benzoylecgonine, a primary metabolite of cocaine, ensuring reliable results.
-
Compliant with Clinical Laboratory Improvement Amendments (CLIA) regulations, supporting use in laboratory settings requiring non-waived testing.
-
Seamlessly integrates with the MedTest 200 Ensemble platform for efficient and effective drug testing processes.
-
Generous 500ml packaging allows for multiple tests, reducing frequency of reorder and enhancing laboratory efficiency.
-
Convenient packaging in a box of two for cost-effectiveness and to meet various testing demands.
Product Specifictions
| Catalog Number/SKU | MF-5390012211 |
| Application | Toxicology Reagent |
|---|---|
| CLIA Classification | CLIA Non-Waived |
| CLIA Classified | CLIA Non-Waived |
| For Use With | For MedTest 200 Ensemble DOA |
| Form | Ready-to-Use Liquid |
| Sample Type | Urine Sample |
| Specialty | Toxicology |
| Storage Requirements | Requires Refrigeration |
| Test Category | Drugs of Abuse |
| Test Name | Cocaine Metabolite (Benzoylecgonine) |
| Test Type | Single Drug |
| Volume | 2 X 500 mL |
